N/A Completed N=214 Randomized Triple-blind Treatment

Evaluation of EverLift in the Performance of Polypectomy for Polyps 4-9mm

Colo-rectal Cancer · Polyp of Colon · Adenomatous Polyp of Colon

Source: ClinicalTrials.gov NCT04551014 ↗

Enrolled (actual)

214

Serious AEs

1.4%

Results posted

Sep 2022

Primary outcomePrimary: Number of Polyps With Complete Resection — 140; 145 Polyps — p=0.424

Summary

The focus of the study is to evaluate impact of submucosal injection of EverLift in achieving complete resection during polypectomy of polyps 4-9mm during colonoscopy.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Polyps With Complete Resection	140; 145	0.424
SECONDARY Time to Resection	109.8; 38.8	<0.0001 sig
SECONDARY Number of Polyps Requiring Multiple Snare Attempts to Achieve Complete Endoscopic Polypectomy.	6; 5	0.697
SECONDARY Number of Patients With Procedural Complications	1; 2	—

Eligibility Criteria

Inclusion Criteria

Patients 18 years or older
Polyps 4-9mm

Exclusion Criteria

Pregnant
Inflammatory bowel disease
Polyposis syndromes

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04551014). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.